fatty liver index grading
Reading File
search_medical_text
fatty liver index FLI grading scoring formula
search_medical_text
hepatic steatosis grading non-alcoholic fatty liver disease NAFLD classification
GradeResponse
GradeResponse
Fatty Liver Index (FLI)
The Fatty Liver Index (FLI) is a non-invasive, blood-based algorithm used to estimate the presence of hepatic steatosis. It was originally developed by Bedogni et al. and validated against ultrasonography, liver histology, and MRI.
Formula
$$FLI = \frac{e^{0.953 \times \ln(TG) + 0.139 \times BMI + 0.718 \times \ln(GGT) + 0.053 \times WC - 15.745}}{1 + e^{0.953 \times \ln(TG) + 0.139 \times BMI + 0.718 \times \ln(GGT) + 0.053 \times WC - 15.745}} \times 100$$
Variables:
| Variable | Description | Units |
|---|---|---|
| TG | Triglycerides | mg/dL |
| BMI | Body Mass Index | kg/m² |
| GGT | Gamma-glutamyl transferase | U/L |
| WC | Waist circumference | cm |
Grading / Interpretation
| FLI Score | Interpretation |
|---|---|
| < 30 | Fatty liver ruled out (sensitivity ~87%) |
| 30 – 59 | Indeterminate — further evaluation may be needed |
| ≥ 60 | Fatty liver ruled in (specificity ~86%) |
Clinical Performance
- AUROC: 0.84 (original Bedogni cohort)
- Sensitivity range across studies: 44–100%
- Specificity range: 3–91%
- AUROC range: 0.59–0.86 depending on population and cutoff used
Key Points
- FLI < 30 effectively excludes hepatic steatosis and can be used to avoid further imaging in low-risk patients.
- FLI ≥ 60 is a reliable indicator for the presence of fatty liver, correlating with >5% steatosis on histology — the threshold used to define NAFLD/MAFLD.
- A modified FLI for North American populations incorporates age, race/ethnicity, fasting insulin, and glucose, and shows improved performance in US cohorts.
- FLI is widely used in epidemiological research and as a screening tool in metabolic syndrome workups, given it requires only routine laboratory and anthropometric measurements.
Context: NAFLD/MAFLD Definition
Fatty liver is formally defined as >5% steatosis on histology (or equivalent on imaging). The condition has been reclassified from NAFLD to MAFLD (Metabolic-dysfunction Associated Fatty Liver Disease) by expert consensus in 2020, though the NAFLD terminology remains prevalent in the literature. FLI thresholds align with this histological cutoff.
homa ir formula
search_medical_text
HOMA-IR formula insulin resistance calculation interpretation
GradeResponse
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)
Developed by Matthews et al. (1985), HOMA-IR is the most widely used surrogate marker of insulin resistance in clinical and research settings.
Formula
$$HOMA\text{-}IR = \frac{Fasting\ Insulin\ (\mu U/mL) \times Fasting\ Glucose\ (mg/dL)}{405}$$
Or, if glucose is in mmol/L:
$$HOMA\text{-}IR = \frac{Fasting\ Insulin\ (\mu U/mL) \times Fasting\ Glucose\ (mmol/L)}{22.5}$$
Both samples must be drawn fasting (minimum 8 hours).
Interpretation
| HOMA-IR Value | Interpretation |
|---|---|
| < 1.0 | Optimal insulin sensitivity |
| 1.0 – 1.9 | Normal range (general population) |
| ≥ 2.0 | Early / borderline insulin resistance |
| ≥ 2.5 | Insulin resistance (commonly used cutoff) |
| ≥ 3.0 | Significant insulin resistance |
| ≥ 5.0 | Severe insulin resistance |
The most widely cited clinical cutoff is ≥ 2.5, though some guidelines use ≥ 2.0 or ≥ 3.0 depending on population.
Key Points
- Fasting state is mandatory — even a small meal significantly raises insulin levels and invalidates the result.
- HOMA-IR correlates well with the gold standard euglycemic hyperinsulinemic clamp at normal glucose levels but performs less reliably in diabetes or severe hyperglycemia.
- Cutoff values vary by ethnicity, age, BMI, and lab assay — no single universal threshold applies to all populations.
- Commonly used in workups for metabolic syndrome, NAFLD/MAFLD, PCOS, prediabetes, and cardiovascular risk stratification.
- A rising HOMA-IR over time is more clinically meaningful than a single value.
Relationship with FLI
HOMA-IR and FLI are complementary tools — HOMA-IR reflects the metabolic/hormonal axis of insulin resistance, while FLI reflects the hepatic/adiposity axis. Elevated values in both strongly support the diagnosis of MAFLD and metabolic syndrome.
apo b reference range
search_medical_text
apolipoprotein B reference range normal values cardiovascular risk
GradeResponse
Apolipoprotein B (Apo B) — Reference Range
Normal Reference Ranges
| Population | Desirable (mg/dL) | Borderline High (mg/dL) | High (mg/dL) |
|---|---|---|---|
| General adults | < 90 | 90 – 109 | ≥ 110 |
| Low/moderate CV risk | < 100 | — | ≥ 100 |
| High CV risk | < 80 | — | ≥ 80 |
| Very high CV risk (established ASCVD, diabetes) | < 70 | — | ≥ 70 |
Values vary slightly by laboratory; most labs report a general normal range of 52–109 mg/dL for adults.
Therapeutic Targets by Risk Category
| Risk Category | Apo B Target |
|---|---|
| Primary prevention, low risk | < 100 mg/dL |
| High cardiovascular risk | < 80 mg/dL |
| Very high risk / established ASCVD | < 70 mg/dL |
| Extreme risk (recurrent ACS, familial hypercholesterolemia) | < 60 mg/dL |
Why Apo B Matters
- Each atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)) carries exactly one Apo B molecule, so Apo B directly reflects total atherogenic particle burden.
- Evidence from the AMORIS, Nurses' Health, and INTERHEART studies shows Apo B is equivalent or superior to LDL-C and non-HDL-C for cardiovascular risk prediction.
- Among patients on statins who achieved LDL-C ≤ 100 mg/dL, LDL-C lost its predictive value for cardiovascular events while Apo B remained significantly associated (MRCT pooled analysis, HR 1.19, P<0.001).
- The Apo B : Apo A-I ratio is one of the strongest predictors of MI — in INTERHEART, the highest vs. lowest decile carried an OR of 4.73 (99% CI 3.93–5.69).
Apo B vs. Other Lipid Markers
| Marker | Reflects | Limitations |
|---|---|---|
| LDL-C | Cholesterol in LDL only | Underestimates risk in metabolic syndrome, hypertriglyceridemia |
| Non-HDL-C | Cholesterol in all atherogenic particles | Affected by cholesterol enrichment of particles |
| Apo B | Number of all atherogenic particles | Best marker when LDL-C and non-HDL-C are discordant |
Clinical Tip
Apo B is particularly valuable when LDL-C appears normal but cardiovascular risk remains high — a pattern seen in metabolic syndrome, insulin resistance, type 2 diabetes, and hypertriglyceridemia, where small dense LDL particles are numerous but cholesterol-poor. In these cases, Apo B unmasks residual risk that LDL-C misses.
This is a shared conversation. Sign in to Orris to start your own chat.